Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US ...
FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback